MRVL Pet Pharmaceuticals Corp.

Recent News

  • MRVL Pet Pharmaceuticals(TM) Announces Management Changes

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - MRVL Pet Pharmaceuticals™ Corp. ("MRVL"), a life sciences and technology company focused on the animal health sector, is pleased to announce the appointment of Ms. Patricia Trompeter as Interim Chief Executive Officer and Mr. John Gamble as a director and Chief Financial Officer of MRVL, effective July 28, 2021, following the resignations of Dr. Joel Navratik, as a director, Chief Executive Officer and President of MRVL and Ivan Hsu as...

    2021-07-30 2:28 PM EDT
  • MRVL Pet Pharmaceuticals(TM) Corp. Announces Changes to Management and Board of Directors

    Toronto, Ontario--(Newsfile Corp. - May 31, 2021) - MRVL Pet Pharmaceuticals™ Corp. (the "Company" or "MRVL"), a life sciences and technology company focused on the animal health sector, is pleased to announce the appointments of Dr. Joel Beth Navratik, current Chief Executive Officer ("CEO") of the Company, as President and a Director of the Company, and Ivan Hsu as Chief Operating Officer ("COO") and Chief Financial Officer ("CFO") of the Company, effective May 31, 2021, following the resignations of Derrick...

    2021-05-31 8:07 PM EDT
  • MRVL Pet Pharmaceuticals(TM) Executes Agreement with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products

    Renowned Veterinary Expert Dr. Albert Ahn Appointed Chief Researcher of Clinical TrialDeborah Cenci, A.V.P of Regulatory Affairs, Quality and Compliance at Altran, Appointed Clinical Trial ManagerToronto, Ontario and Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) - MRVL Pet Pharmaceuticals™ Corp. (the "Company" or "MRVL"), a life sciences and technology company focused on the animal health sector, today announced it has entered into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services...

    2021-03-16 9:03 AM EDT
  • MRVL PET PHARMA Closes Financing at $4.246 Million, Appoints New CEO, Effects Name Change and Announces Spinout of Medical Device Technology

    Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - MRVL Pet Pharmaceuticals Corp. (the "Company" or "MRVL") announced today that it has closed on a total of $4,245,653 with the closing of a 2nd tranche (final) of the private placement of 6,548,268 units at a price of $0.325 per unit for gross proceeds of $2,128,187. Each unit consisted of one common share and a half warrant. Each whole warrant will entitle the subscriber to purchase an additional common...

    2021-02-10 5:11 PM EST
  • EGF Health Increases Private Placement to $4 Million and Announces Name Change

    Vancouver, British Columbia--(Newsfile Corp. - January 29, 2021) - EGF Health Holdings Corp. (the "Company") announced today that it has increased its private placement to up to 12,307,692 units at a price of $0.325 per unit for gross proceeds of up to $4,000,000. Each unit consists of one common share and a half warrant. Each whole warrant will entitle the subscriber to purchase an additional common share at an exercise price of $0.50 per share for a period of...

    2021-01-29 8:50 PM EST
  • EGF Health Closes Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - January 13, 2021) - EGF Health Holdings Corp. announced today that it has closed a private placement of 6,515,277 units at a price of $0.325 per unit for gross proceeds of $2,117,465. Each unit consisted of one common share and a half warrant. Each whole warrant will entitle the subscriber to purchase an additional common share at an exercise price of $0.50 per share on or before January 8, 2022. Finder's fees of $43,973...

    2021-01-13 8:19 PM EST
  • EGF Health Announces Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - January 8, 2021) - EGF Health Holdings Corp. announced today a private placement of up to 7,692,307 units at a price of $0.325 per unit for gross proceeds of up to $2,500,000. Each unit consists of one common share and a half warrant. Each whole warrant will entitle the subscriber to purchase an additional common share at an exercise price of $0.50 per share for a period of one year from the closing...

    2021-01-08 7:15 PM EST